Results 51 to 60 of about 23,676 (191)
Journal of Experimental & Clinical Cancer ResearchBackground Non-small cell lung cancer (NSCLC) is a significant global health challenge, with 2% of cases fuelled by RET rearrangements. RET inhibitors (RETi) have revolutionized treatment for these patients, but resistance remains an important clinical ...
Daniela Esposito +19 more
doaj +1 more source
Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer
Chinese Journal of Lung Cancer, 2021 Rearranged during transfection (RET) fusions are found in 0.7% to 2% of non-small cell lung cancer (NSCLC). Fusions between RET gene and other domains represent the distinct biological and clinicopathological subtypes of NSCLC.
Qingyun GAO +4 more
doaj +1 more source
Thyroid Research, 2023 Background The discovery of driver oncogenes for thyroid carcinomas and the identification of genomically targeted therapies to inhibit those oncogenes have altered the treatment algorithm in thyroid cancer (TC), while germline testing for RET mutations ...
Suzanne Murray +7 more
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub +3 more
wiley +1 more source
Overview of management and therapeutic advances in medullary thyroid cancer
Endocrine OncologyMedullary thyroid carcinoma (MTC) is a rare cancer of the thyroid’s calcitonin-producing C cells. This review covers recent advances in MTC treatment, emphasizing surgical and systemic therapies.
Mark A Jara, Luciana Audi Castroneves
doaj +1 more source
Precision oncology with selective RET inhibitor selpercatinib in -rearranged cancers
Therapeutic Advances in Medical Oncology, 2023 Rearranged during transfection ( RET ) is a protooncogene that encodes for receptor tyrosine kinase with downstream effects on multiple cellular pathways.
Mohamed A. Gouda, Vivek Subbiah
doaj +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Selpercatinib: A narrative drug review
Cancer Research, Statistics, and TreatmentRearranged during transfection (RET) alteration promotes oncogenesis in a few cancers. RET mutation positivity is seen in approximately 70% of medullary thyroid cancers, around 30% of differentiated papillary thyroid cancers, and 1-2% of non-small-cell ...
Priyadarshini Eashwar Raj +2 more
doaj +1 more source
Biotechnology and Bioengineering, EarlyView.Genetic engineering (GE) overcomes BCA limits, enabling robust, scalable crop protection. “Super Bioagents” (SBs) use optimized SSs to enhance bioactive molecule delivery. Optimizing SSs enhance precise, sustainable effector deployment for stable disease suppression. SBs use microbiome‐informed design for scalable, next‐gen sustainable crop protection.
Michael Dare Asemoloye
wiley +1 more source
Targeting RET-rearranged non-small-cell lung cancer: future prospects
Lung Cancer: Targets and Therapy, 2019 Giuseppe Bronte, Paola Ulivi, Alberto Verlicchi, Paola Cravero, Angelo Delmonte, Lucio Crinò Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy Abstract: Non-small ...
Bronte G +5 more
doaj